In the past number of years, the UK has witnessed a revolution in medical excess weight‑decline treatment options — within the introduction of semaglutide (Wegovy®) into the rising reputation of tirzepatide (Mounjaro®). Now, An additional name is drawing interest in both of those clinical and pub